Also trades as: 0VGI.L (LSE) · $vol 1M
TGTX NASDAQ
TG Therapeutics, Inc.
1W: +3.5%
1M: +0.4%
3M: +5.5%
YTD: +92.8%
1Y: +69.3%
3Y: +736.1%
5Y: +77.0%
$56.44
+1.65 (+3.01%)
Weekly Expected Move ±4.9%
$49
$52
$54
$57
$59
Credit Risk of going bust: lower than 68% of companies Debt: 8.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.46 (down 99.2%), TG Therapeutics, Inc. would be worth roughly what it owes.
Total debt $754.4M against a stock market value of $8.64B.
Distance to default 7.24 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $372.7M (short-term plus half of long-term), stock volatility 45.1%; Altman Z'' 2.57. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.46 (down 99.2%), TG Therapeutics, Inc. would be worth roughly what it owes.
Total debt $754.4M against a stock market value of $8.64B.
Distance to default 7.24 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $372.7M (short-term plus half of long-term), stock volatility 45.1%; Altman Z'' 2.57. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
4 relationships3
As Filer
counterparties named
1
As Counterparty
mentioned by others
1
Rel. Types
2023-08-01
Earliest Filing
2024-08-06
Latest Filing
partner: 3
Counterparties (Filed by TGTX)
3 relationshipsCompanies named in TGTX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Neuraxpharm | — | partner | Counterparty to commercialization agreement for BRIUMVI in EU | 2024-08-06 | View |
| Precision BioSciences | DTIL | partner | Counterparty to license agreement | 2024-08-06 | View |
| Neuraxpharm Pharmaceuticals, S.L. | — | partner | Exclusive license agreement for commercialization of BRIUMVI in Europe and certain territories outside the US. | 2023-08-01 | View |
Mentioned As Counterparty
1 mentionsOther companies that named TGTX in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-03 | Earnings Release; Exhibits | View | |
| 2026-06-12 | Shareholder Vote | View | |
| 2026-06-03 | Other Events; Exhibits | View | |
| 2026-05-27 | Other Events; Exhibits | View | |
| 2026-05-06 | Earnings Release; Exhibits | View | |
| 2026-03-20 | Material Agreement; Financial Obligation; Exhibits | Agreement | View |
| 2026-02-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-13 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-03 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-13 | Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits | View | |
| 2025-05-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-03 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-14 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2024-11-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-08-06 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement; Results of O | Agreement | View |
| 2024-06-17 | Departure/Election of Directors; Appointment of Officers; Amendments to Articles of Incorporation or | View | |
| 2024-01-10 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2023-11-01 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2023-08-01 | Entry into Material Definitive Agreement; Results of Operations and Financial Condition; Financial S | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR